(MedPage Today) — TORONTO — An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer’s disease, researchers said here.
Continued…
Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116807
Author :
Publish date : 2025-08-03 17:53:00
Copyright for syndicated content belongs to the linked Source.
